For Quick Alerts
For Daily Alerts

Aurobindo Pharma Shares Slumps 10% On Termination Of Agreement With Sandoz


Shares in Aurobindo Pharma slumped as much as 10 per cent, after the company said that it has decided to terminate the agreement with Sandoz.

"Aurobindo today announced the mutual agreement with Sandoz Inc to terminate the agreement to buy the Sandoz US generic oral solids and dermatology businesses from Sandoz Inc. This decision was taken as approval from the U.S .S. Federal Trade Commission for the transaction was not obtained within anticipated timelines," the company said in a release to the exchanges.

Aurobindo Pharma Shares Slumps 10% On Termination Of Agreement With Sandoz

Aurobindo Pharma is one of India's leading pharma companies. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and AntiDiabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

Story first published: Friday, April 3, 2020, 9:57 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more